Why Is Myriad Genetics Still Filing Patent Suits for Breast-Cancer Tests?

The Supreme Court declared human genes unpatentable, but it didn’t free the market for genetic testing.

National Journal
Brian Resnick
Add to Briefcase
Brian Resnick
Aug. 8, 2013, 8:28 a.m.

You can’t pat­ent a piece of the hu­man gen­ome, the Su­preme Court de­clared in a un­an­im­ous de­cision in June. So why, in the weeks after, did Myri­ad Ge­net­ics — the com­pany whose pat­ents were voided — sue a com­pet­it­or for pat­ent in­fringe­ment for test­ing for the very gene de­clared un­pat­entable by the Court?

Some back­ground: In the case, the As­so­ci­ation for Mo­lecu­lar Patho­logy brought suit against Myri­ad be­cause it thought it one com­pany shouldn’t have the sole rights to a seg­ment of the hu­man gen­ome — es­pe­cially when that seg­ment in­dic­ates a per­son’s breast-can­cer risk. The or­gan­iz­a­tion ar­gued that Myri­ad’s mono­poly of test­ing for the ma­lig­nant vari­ants of the BRCA1 and BRCA2 genes plugged up in­nov­a­tion in the sci­ence and drove up costs for pa­tients. Those with a cer­tain vari­ant of these genes have a 60 per­cent like­li­hood of de­vel­op­ing breast can­cer. If you re­call, the act­ress An­gelina Jolie dis­covered she was a car­ri­er for the gene, which promp­ted her to un­der­go a double mastec­tomy to void the risk.

The Su­preme Court largely agreed with the As­so­ci­ation for Mo­lecu­lar Patho­logy, de­clar­ing slices of the nat­ur­ally oc­cur­ring hu­man gen­ome un­fit for pat­ents. And right after the de­cision, two com­pan­ies — Ambry Ge­net­ics and Gene By Gene — saw an open­ing to start of­fer­ing the  breast-can­cer screen­ing tests that Myri­ad had been per­form­ing. And then Myri­ad sued … for pat­ent in­fringe­ment.

The short an­swer to how Myri­ad could jus­ti­fy its move is this: Sci­ence is so very com­plic­ated, and the Court ruled nar­rowly.

In its de­cision, the Su­preme Court main­tained that man-made cop­ies of hu­man DNA were still pat­entable. These pieces are called cDNA, which are slightly altered cop­ies of the nat­ur­ally oc­cur­ring genes. They are use­ful tools for ge­net­ic test­ing, since they can be used to re­lay a per­son’s ge­net­ic in­form­a­tion in a stable form. This bit of the rul­ing, in ef­fect, al­lows Myri­ad to still lay claim to much of the breast-can­cer test­ing.

Writ­ing in Sci­entif­ic Amer­ic­an, Megan Krench, a ge­net­i­cist, provides a more de­tailed an­swer (Read­er’s Di­gest ver­sion: While the Court took away Myri­ad’s castle, they left them the moat):

Why do Myri­ad’s pat­ent rights to cDNA mat­ter? There are sev­er­al reas­ons. First, cDNA is an im­port­ant re­search tool. For ex­ample, the ed­ited cDNA se­quence, not the longer DNA se­quence, is of­ten used to cre­ate an­im­al mod­els of dis­eases. Those mod­els are es­sen­tial for re­search­ing new treat­ments and cures. Without the li­cens­ing to BRCA1/2 cDNA, cer­tain can­cer re­search may be re­stric­ted to Myri­ad. Next, cDNA is crit­ic­al for de­vel­op­ing new dia­gnost­ic tests for ge­net­ic dis­orders. Since the BRCA1/2 genes them­selves are not pat­en­ted, it may be pos­sible for oth­er com­pan­ies to de­vel­op new ge­net­ic tests — but the pat­en­ted cDNA will make this pro­cess much more dif­fi­cult.

In all, after the Court’s de­cision, Myri­ad ar­gues in the doc­u­ments filed against Ambry, it has re­tained 515 of 520 pat­ent claims re­gard­ing the test.

This is­sue is go­ing to get an­oth­er go-around in the courts, as Ambry has coun­ter­sued, cit­ing an­ti­trust vi­ol­a­tions. A lot of money is at stake here for Myri­ad and its com­pet­it­ors. Ac­cord­ing to Ars Tech­nica, Myri­ad hauled in $57 mil­lion from the tests that can cost $3,000 or more. And the in­tro­duc­tion of com­pet­it­ors, however brief, pushed the mar­ket price way down: Ambry star­ted to sell the tests for $2,280; Gene by Gene offered a re­l­at­ive steal at $995. The ge­net­ic-test­ing in­dustry is on the verge of boom­ing, as I re­por­ted in June. By 2021, the na­tion­al costs for ge­net­ic test­ing could rise to $25 bil­lion. Right now, they are around $5 bil­lion.

What We're Following See More »
THE PLAN ALL ALONG?
Manchin Drops Objections, Clearing Way for Spending Deal
16 hours ago
THE LATEST

"The Senate standstill over a stopgap spending bill appeared headed toward a resolution on Friday night. Senators who were holding up the measure said votes are expected later in the evening. West Virginia Democrat Joe Manchin had raised objections to the continuing resolution because it did not include a full year's extension of retired coal miners' health benefits," but Manchin "said he and other coal state Democrats agreed with Senate Democratic leaders during a caucus meeting Thursday that they would not block the continuing resolution, but rather use the shutdown threat as a way to highlight the health care and pension needs of the miners."

Source:
UNCLEAR WHAT CAUSED CHANGE OF HEART
Giuliani Out of Running For State
18 hours ago
BREAKING

Donald Trump transition team announced Friday afternoon that top supporter Rudy Giuliani has taken himself out of the running to be in Trump's cabinet, though CNN previously reported that it was Trump who informed the former New York City mayor that he would not be receiving a slot. While the field had seemingly been narrowed last week, it appears to be wide open once again, with ExxonMobil CEO Rex Tillerson the current favorite.

Source:
ALSO VICE-CHAIR OF TRUMP’S TRANSITION TEAM
Trump Taps Rep. McMorris Rodgers for Interior Secretary
23 hours ago
BREAKING
SHUTDOWN LOOMING
House Approves Spending Bill
1 days ago
BREAKING

The House has completed it's business for 2016 by passing a spending bill which will keep the government funded through April 28. The final vote tally was 326-96. The bill's standing in the Senate is a bit tenuous at the moment, as a trio of Democratic Senators have pledged to block the bill unless coal miners get a permanent extension on retirement and health benefits. The government runs out of money on Friday night.

HEADS TO OBAMA
Senate Approves Defense Bill
1 days ago
THE LATEST

The Senate passed the National Defense Authorization Act today, sending the $618 billion measure to President Obama. The president vetoed the defense authorization bill a year ago, but both houses could override his disapproval this time around.

Source:
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login